← Oncology Approval Tracker

FDA DECISION ·

Datroway

datopotamab deruxtecan-dlnk · Daiichi Sankyo

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with unresectable or metastatic TNBC who are ineligible for PD-1 or PD-L1 inhibitor therapy.

LAMPGEN ANALYSIS

Why it matters

TROPION-Breast02 studied a TROP2 ADC in previously untreated advanced disease in people who could not receive checkpoint inhibitor therapy. Keep the trial line and labeled population clear.

What research teams should watch

Record checkpoint inhibitor ineligibility and the pretreatment history. Include pulmonary symptom escalation and oral toxicity surveillance when discussing monitoring.

PRIMARY RECORDS

Sources